ONTARGET (ASSOCIATION VS RAMIPRIL) 2008

NCT00153101

A randomised clinical trial investigating the effect of telmisartan + ramipril versus ramipril in patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage

1 Treatments

<table>
<thead>
<tr>
<th>Studied treatment</th>
<th>telmisartan 80mg + ramipril 10mg daily</th>
</tr>
</thead>
</table>

Control treatment  
ramipril 10 mg daily

Concomittant treatments

2 Patients

<table>
<thead>
<tr>
<th>Patients</th>
<th>patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage</th>
</tr>
</thead>
</table>

3 Methods

<table>
<thead>
<tr>
<th>Blinding</th>
<th>double blind</th>
</tr>
</thead>
<tbody>
<tr>
<td>Design</td>
<td>Parallel groups</td>
</tr>
<tr>
<td>Centers</td>
<td>733</td>
</tr>
<tr>
<td>Geographical area</td>
<td>40 countries</td>
</tr>
</tbody>
</table>

| Sample size | 17078 (8502 / 8576) |
| ArretTrt1   | - |
| ArretTrt0   | - |
| PeriodInclusion | - |
| Hypothe  
se | Non inferiority |
## 4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>revascularisation</td>
<td>1303/8501</td>
<td>1269/8576</td>
<td>1,04</td>
<td>[0,95; 1,13]</td>
</tr>
<tr>
<td>Ev. coronariens</td>
<td>438/8501</td>
<td>413/8576</td>
<td>1,07</td>
<td>[0,93; 1,23]</td>
</tr>
<tr>
<td>nouveau diabète</td>
<td>323/8501</td>
<td>366/8576</td>
<td>0,89</td>
<td>[0,76; 1,04]</td>
</tr>
<tr>
<td>Infarctus non mortel</td>
<td>-/8501</td>
<td>-/8576</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>HOPE endpoint</td>
<td>-/8501</td>
<td>-/8576</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>AVC mortels et non mortels</td>
<td>373/8501</td>
<td>405/8576</td>
<td>0,93</td>
<td>[0,80; 1,07]</td>
</tr>
<tr>
<td>Mortalité totale</td>
<td>1386/8501</td>
<td>1412/8576</td>
<td>0,99</td>
<td>[0,91; 1,07]</td>
</tr>
<tr>
<td>PAS</td>
<td>-/8501</td>
<td>-/8576</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>EUROPA endpoint</td>
<td>-/8501</td>
<td>-/8576</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Décès cardiovasculaires</td>
<td>620/8501</td>
<td>603/8576</td>
<td>1,04</td>
<td>[0,92; 1,17]</td>
</tr>
<tr>
<td>Mortalité totale</td>
<td>1065/8501</td>
<td>1014/8576</td>
<td>1,06</td>
<td>[0,97; 1,16]</td>
</tr>
<tr>
<td>PAD</td>
<td>-/8501</td>
<td>-/8576</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>PEACE endpoint</td>
<td>-/8501</td>
<td>-/8576</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Ev. cardiovasculaires</td>
<td>1200/8501</td>
<td>1210/8576</td>
<td>1,00</td>
<td>[0,92; 1,09]</td>
</tr>
<tr>
<td>Décès coronariens</td>
<td>-/8501</td>
<td>-/8576</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cancer occurrence</td>
<td>-/8502</td>
<td>735/8576</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cancer occurrence (as prespecified endpoint)</td>
<td>-/8502</td>
<td>-/8576</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Arrêt pour effet secondaire</td>
<td>2495/8501</td>
<td>2099/8576</td>
<td>1,20</td>
<td>[1,12, 1,28]</td>
</tr>
<tr>
<td>Insuffisance rénale</td>
<td>94/8501</td>
<td>60/8576</td>
<td>1,58</td>
<td>[1,14; 2,19]</td>
</tr>
<tr>
<td>Toux</td>
<td>392/8501</td>
<td>360/8576</td>
<td>1,10</td>
<td>[0,95; 1,27]</td>
</tr>
<tr>
<td>Angiodème</td>
<td>18/8501</td>
<td>25/8576</td>
<td>0,73</td>
<td>[0,40; 1,33]</td>
</tr>
<tr>
<td>hypotension</td>
<td>406/8501</td>
<td>149/8576</td>
<td>2,75</td>
<td>[2,27; 3,32]</td>
</tr>
</tbody>
</table>

## 5 References


## 6 Comments